NIH RFA-DA-25-024: High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

NIH RFA-DA-25-024: High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

RFA-DA-25-024 is an NIH funding opportunity from NIDA and the Office of the Director (OD) open through the NOFO extension published in 2026. It targets the direct overlap between HIV and substance use disorders, with a clear intent to fund projects that can produce prevention, treatment, and cure-relevant advances for people who use addictive substances. The page is a standard NIH RFA and lists recurring due dates and cycles through 2026 and into 2027, which makes it useful for teams planning a proposal in this planning window rather than a narrow one-off submission.

What this opportunity is exactly

This NOFO requests NIH R01 proposals and explicitly states that projects should be high-priority work at the intersection of HIV and substance use, with attention to clinical and public health impact. The official title is:

High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)

and the funding opportunity number is RFA-DA-25-024. The key elements are:

• It is an R01-style research project grant.
• It is a reissue of an earlier opportunity (RFA-DA-22-040).
• It is not limited to one discipline; the NOFO invites basic science, epidemiology, clinical, intervention, and implementation work.
• It is designed to support teams working on HIV and substance use together rather than parallel but disconnected projects.

The text also makes it clear that applications should not be generic HIV proposals; they must show a meaningful nexus with substance use and include a concrete and credible research plan with preliminary evidence. That is a strong filter in review and a practical reminder for applicants: this is not a place for broad HIV concept papers without substance-use relevance.

Why this is relevant for 2026/2027 cycles

At the top of the timeline, this NOFO is set with multiple cycles and an explicit extension into 2027:

• The page shows a posted date in 2024, first open date in 2025, and a revised expiration date of March 6, 2027.
• Multiple review and award milestones are listed across 2026 and 2027.
• It includes a committed budget statement for FY2025, FY2026, and FY2027.

For the specific user intent “Target opportunity years: 2026 and 2027,” this matches well because it remains a 2026/27-cycle program and is not a one-time historical announcement. Even if some due windows are before or near your date, the published expiration date and cycle structure signal that teams can still align proposals with the stated window.

Key details at a glance

Eligibility and fit: who this is for

The NOFO lists unusually broad applicant-organization eligibility and is one of the points that makes this opportunity easier to target than many tightly constrained institute programs. It includes:

• Higher Education Institutions
• Nonprofits (including 501(c)(3) and non-501(c)(3) types)
• For-profit organizations (including small businesses)
• State, city, county, and other local governments
• Federally recognized and some non-recognized tribal governments
• Public housing authorities, regional organizations, and tribal organizations
• U.S. federal agencies and U.S. territory entities
• Foreign entities (non-domestic components are eligible)

For applicants, the practical interpretation is:

1. Teams should think about data and implementation context first.
2. The program is not restricted to a single field or career stage, but the scope demands clear HIV+SUD integration.
3. International applicants should still verify program-specific policy compliance and registration workflow with NIH systems before final submission.

If your team includes investigators with existing HIV cohorts, implementation partnerships in treatment settings, or expertise in behavioral interventions for substance use and HIV prevention, this opportunity is likely a better fit than a standard biomedical-only bid.

Eligibility checklist: people and project fit

Before you begin a full draft, test your project against the core fit criteria below:

• Is HIV infection and substance use connected in the same analytic design?
• Does the proposal show preliminary data or a clear data-generation plan?
• Is there a direct path from question to prevention, treatment, care continuity, or cure outcomes?
• Can you specify implementation relevance (delivery, access, adherence, integration, or service models)?
• Do you clearly identify how your design addresses an HIV/SUD research gap?
• If your team lacks HIV-SUD integration experience, do you have collaborators with those competencies?

A proposal with excellent science but weak HIV-SUD integration is likely to fail this NOFO’s intent filter, even before technical review.

What the NOFO says about funding and grant mechanics

The strongest concrete fact from the official page is the budget envelope:

• NIH states it intends to commit $3.0 million in FY2025, FY2026, and FY2027.
• It expects 3–5 awards overall.

Unlike NOFOs with strict budget ceilings per award, this one states the total commitment and indicates that application budgets are not explicitly limited, with the standard rule that requested budgets should reflect actual project needs. In practical terms, reviewability is more likely driven by scientific quality, HIV/SUD alignment, and feasibility than by arbitrary spending caps. Still, this does not mean “unbounded funding”; budget justification should be realistic, and budgets that overreach on staff without scientific necessity or data burden can create concerns in peer and programmatic review.

A max project period of 5 years is listed for these applications, which is significant for intervention and implementation proposals that need phased rollout and follow-up.

Application timeline and deadlines you should track

The key dates are easy to misread because the NOFO uses stacked due and review windows. At minimum:

• LOI is generally due 30 days before an application due date.
• Applications have multiple submission windows across cycles.
• NOFO expiration is listed as March 6, 2027 (updated).
• The NIH page shows review and award sequence lines extending through 2027 cycles.

For applicants in 2026, treat this as an active cycle strategy:

1. Identify your nearest published due date and LOI date before project start.
2. Set internal freeze date at least 10 business days before NIH systems deadline.
3. Keep at least one full internal review window for summary statements and administrative fixes, even if you are using institutional submission support.
4. Use the repeated cycle nature as an advantage: if your first submission misses a target date, you can reframe for the next deadline while preserving your core assets.

Because the NOFO includes many windows and not a single closeout date, planning should be based on the latest official cycle and internal deadlines, then cross-checked every time NIH updates the NOFO or posting references.

Application package: what to prepare first

The NOFO is an NIH R01 with clinical trial flexibility, so your package should be built like a standard strong R01 but explicitly tailored to HIV/SUD convergence. Practical priority is to avoid generic “all-viable” narratives.

Core proposal components

• Specific Aims: define one HIV endpoint and one substance use mechanism endpoint in one coherent framework.
• Research Strategy: split by significance, innovation, and approach with clear pathway from intervention to outcome.
• Preliminary Data: this is explicitly important; proposals without a data foundation should carry stronger justification and methodological safeguards.
• Environment: show where recruitment, treatment integration, and outcome tracking can be executed.
• Human Subjects and data plans: this area must align with NIH expectations and be complete before final submission.
• Data Management and Sharing: required for all applications by NIH policy.

Practical sequence for a clean submission

1. Build an internal concept sheet with one-page aims and hypotheses.
2. Draft a methods diagram that maps HIV outcome and substance-use pathway in one model.
3. Prepare recruitment and retention logic for populations affected by both HIV and SUD.
4. Secure internal institutional sign-offs (safety, compliance, clinical governance, data agreements).
5. Draft administrative attachments and forms in parallel with narrative writing.
6. Schedule a final “readability pass” that checks alignment with each Aims bullet in the NOFO list.

Review expectations and how to frame your response

The NOFO explicitly prioritizes projects that can open “new areas of HIV/AIDS research” and move prevention/treatment/cure agendas for people who use substances. That means projects are evaluated for strategic alignment as much as technical sophistication.

Strong themes to emphasize:

• Direct relevance to populations where HIV prevention, care, and substance-use treatment overlap.
• Mechanistic clarity or practical implementation value.
• Methodological rigor where multiple comorbidities and longitudinal effects are expected.
• Feasibility in real-world settings (clinical or community implementation potential).

Reviewer pitfalls are often avoidable:

• Framing as separate HIV and SUD projects without a single shared hypothesis.
• Using vague endpoints not linked to HIV transmission, treatment retention, or care continuum outcomes.
• Underdeveloped recruitment realism or underestimating population-level heterogeneity.
• Weak preliminary data for high-risk mechanism claims.

Recommended strategy by candidate profile

Academic PI with existing NIH ecosystem support

Use your existing NIH grants infrastructure and submit quickly; prioritize scientific novelty plus integration. Include strong DMS and human subjects sections early, since NIH administrative checks can become the first failure point.

Small nonprofit or community-affiliated team

Lead with implementation outcomes and partnership credibility. Document community pathway access, clinical referral pathways, and measurable implementation endpoints. Tie evaluation measures directly to HIV/SUD public health impact.

For-profit or small business

Use this where there is a translational angle tied to implementation in care settings. The NOFO permits for-profit applicants; however, the scientific argument must still prioritize public health and translational rigor. Show that commercialization is not the primary end; evidence generation and impact for HIV/SUD are.

International organization or foreign component

Check NIH submission and compliance expectations before writing. The opportunity indicates foreign entities can be eligible, but administrative requirements may be heavier than for domestic institutions. If in doubt, start from your local grants office and NIH-assigned administration contact points.

Risks, common mistakes, and mitigation

Common mistakes observed with this type of NOFO include:

1. Misreading the cycle schedule

   • Mistake: assuming a single annual deadline.
   • Fix: treat it as cycle-based and use the published sequence.

2. Weak statement of nexus between HIV and substance use

   • Mistake: proposals discuss HIV and SUD as parallel sections.
   • Fix: force every aim to carry a shared mechanism.

3. Insufficient preliminary support for high-risk claims

   • Mistake: over-promising without pilots.
   • Fix: include preliminary data and a transparent risk-mitigation plan.

4. Late administrative preparation

   • Mistake: assuming registrations and sponsor links can be finished at the end.
   • Fix: set registry and compliance milestones at least one cycle ahead.

5. Ignoring implementation realities

   • Mistake: elegant design with no plausible deployment model.
   • Fix: add site, staffing, and integration plan in the approach section.

If one of these risks is strong in your proposal, use a short “alignment pass” right before submission: each paragraph should answer either HIV relevance, SUD relevance, or the integration mechanism.

Preparation timeline (suggested)

Below is a practical one-cycle template you can copy into your project plan:

• T-16 weeks: finalize partner agreements, define intervention model, confirm target population.
• T-12 weeks: lock Specific Aims, begin full narrative draft, and map data sources.
• T-10 weeks: route for internal pre-review (science + compliance).
• T-6 weeks: integrate revisions, complete required registrations, and assemble appendix.
• T-3 weeks: submit internal pre-submission test, verify file packages and forms.
• T-1 week: final internal proofread for NOFO alignment and LOI timing.
• Submission date: submit early; avoid same-day fixes.

Official links to use

Use the official NIH NOFO page for all references:

• Primary NOFO: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html
• Companion opportunities listed by NIH: RFA-DA-25-060 and RM1 complex structure options linked from the same page.
• NIDA/NIH policy links included on the page for clinical trial determination and grant administration.

Because this opportunity is NIH-issued, these links are the official source of truth. Do not rely on third-party summaries for compliance details.

FAQ

Is this opportunity currently open?

The NOFO page shows an updated expiration of March 6, 2027 and cycle listings that span 2026/2027, so it was actively usable for planning in this period. Confirm any final cycle deadline on the NIH page before you submit.

Is NIH limiting applicants to clinical trials?

No. The RFA states clinical trials are optional.

Are there strict budget limits?

The page does not list a fixed per-application cap. It explicitly states an total FY2025-27 intent and expected 3–5 awards. Budgets should be justified by project scope.

Are renewals allowed?

Yes. New, renewal, resubmission, and revision application types are listed as allowed in the NOFO.

Can small businesses apply?

Yes, for-profit organizations including small businesses are eligible.

Does this support international entities?

The eligibility section includes foreign organizations as eligible applicants.

What to submit next

If this matches your team profile, the fastest next step is to create a one-page concept map with these fields:

• HIV outcome of interest
• Substance use outcome of interest
• Shared mechanism
• Proposed study population
• Primary endpoints and timeline
• Required partnerships or data resources
• Anticipated risks and contingencies

Then compare it against the NOFO language section-by-section. If the fit passes, your proposal is in a far better position to survive internal pre-submission reviews and move into official submission on schedule.